(UroToday.com) The 2024 American Urological Association (AUA) Annual Meeting held in San Antonio, TX was host to the International Prostate Forum. Dr. Jeremie Calais presented key updates in radioligand therapy for patients with PSMA-sensitive disease.
The field of prostate cancer theranostics has experienced tremendous growth over the past decade. In 2015, Benesova et al. described one of the earliest experiences with PSMA-targeted Lutetium-177 radioligand therapy, demonstrating biochemical and radiographic responses in patients with advanced prostate cancer.1 This was shortly followed by a report from Kratochwil et al. that similarly demonstrated remission with 177Lu-PSMA in a metastatic prostate cancer patient.2
more links
Enzalutamide and PSMA
ARASENS Trial
Addition of an ARSI to standard ADT significantly increases the risk of fractures and falls in men with prostate cancer
My experience and my thoughts about undergoing radioligand therapy using the PSMA-617 ligand loaded with 177Lu and 225Ac isotopes. Part 1.
